Zevra director exercises options and sells shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Director Corey Michael Watton of Zevra Therapeutics, Inc. exercised stock options for 12,300 shares of common stock at an exercise price of $4.97 per share and on the same date sold 12,300 shares of common stock at a weighted average price of $11.2502 per share, in multiple trades ranging from $11.23 to $11.31. Following the option exercise, Watton held 46,500 stock options that remain outstanding and fully vested under the reported award.
Insider Trade Summary
Exercise and Sale: 12,300 shares ($77K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Watton Corey Michael
Role
Director
Sold
12,300 shs ($138K)
Approx. gross sale proceeds
$138K
Approx. exercise cost
$61K
Approx. pre-tax spread
$77K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F2 | 12,300 | $0.00 | $0.00 |
| Exercise | Common Stock | 12,300 | $4.97 | $61K |
| Sale | Common Stock F1 | 12,300 | $11.2502 | $138K |
Holdings After Transaction:
Stock Option (right to buy) — 46,500 contracts (Direct);
Common Stock — 1,800 shares (Direct)
Footnotes (2)
- F1. This transaction was executed in multiple trades at prices ranging from $11.23 to $11.31. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2. The shares underlying this option, which was granted on May 3, 2023, were fully vested.
Key Figures
Options Exercised: 12,300 shares
Exercise Price: $4.97 per share
Shares Sold: 12,300 shares
+5 more
8 metrics
Options Exercised
12,300 shares
Stock options exercised into common stock on 2026-08-10
Exercise Price
$4.97 per share
Exercise price of stock options converted on 2026-08-10
Shares Sold
12,300 shares
Common stock sold on 2026-08-10 following option exercise
Weighted Average Sale Price
$11.2502 per share
Weighted average for sales executed between $11.23 and $11.31
Price Range of Sales
$11.23–$11.31 per share
Range of individual trade prices for the 12,300 shares sold
Options Remaining
46,500 options
Stock options held after the 12,300-option exercise
Option Expiration Date
2033-05-02
Expiration date of the option grant exercised in part
Option Grant Date
May 3, 2023
Grant date of fully vested options underlying this exercise
Key Terms
Stock Option (right to buy), Exercise or conversion of derivative security, weighted average sale price, fully vested
4 terms
Stock Option (right to buy) financial
"security_title is listed as Stock Option (right to buy)"
Exercise or conversion of derivative security financial
"transaction_code_description states Exercise or conversion of derivative security"
weighted average sale price financial
"The price reported reflects the weighted average sale price"
fully vested financial
"The shares underlying this option ... were fully vested"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Corey Michael Watton report in this Form 4 for ZVRA?
Corey Michael Watton reported exercising 12,300 stock options at $4.97 per share and selling 12,300 common shares at a weighted average price of $11.2502 per share on the same date.
How many Zevra Therapeutics (ZVRA) options did Watton exercise and at what price?
Watton exercised 12,300 stock options for Zevra Therapeutics common stock at an exercise price of $4.97 per share, converting them into an equal number of common shares before the reported sale.
How many Zevra Therapeutics (ZVRA) stock options does Watton still hold after these transactions?
After the reported option exercise, Watton holds 46,500 stock options for Zevra Therapeutics, as shown by the post-transaction derivative holdings figure in the filing data.
Were the ZVRA options exercised by Watton already vested?
Yes. The filing states that the options, granted on May 3, 2023, were fully vested at the time of exercise, meaning all 12,300 underlying shares were exercisable.
Was Corey Michael Watton’s ZVRA Form 4 sale part of a 10b5-1 trading plan?
The document-level indicator shows the Rule 10b5-1 checkbox was not affirmed, and the footnotes do not describe the sale as made under a trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
